Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Anti-Obesity Drug 9604
Also known as: AOD-9604, HGH Fragment 176-191
Confidence
Updated 2026-03-18
AOD 9604 is a modified fragment (amino acids 176-191) of the human growth hormone molecule, designed to retain the fat-burning properties of GH while eliminating its growth-promoting effects. It was originally developed as an anti-obesity pharmaceutical by Metabolic Pharmaceuticals Ltd. in Australia.
Class
GH Fragment / Weight Management
Routes
Subcutaneous, Oral
Half-Life
Not formally established in humans.
Mimics the lipolytic region of growth hormone, stimulating fat breakdown (lipolysis) and inhibiting lipogenesis (fat formation). Does not interact with the GH receptor in a way that promotes IGF-1 elevation, theoretically providing fat loss without the diabetogenic and growth-promoting risks of full-length GH.
Half-Life
Not formally established in humans.
Bioavailability
Not formally established.
No approved indications. Research: fat loss, metabolic optimization, cartilage repair (limited data).
Phase II clinical trials in Australia showed modest weight loss effects. Did not advance to Phase III due to insufficient efficacy relative to emerging GLP-1 therapies. Some animal data on cartilage repair. Overall clinical evidence is weak.
Human Studies
5
Animal Studies
20
Limited human safety data. Generally reported as well-tolerated in available trials. Immunogenicity concerns raised by FDA.
PCAC rejected (October 2024). Prohibited from compounding. TGA (Australia) approved as a food supplement ingredient — regulatory status varies by country.
Drug Interactions: Unknown. Research Gaps: Failed to demonstrate clinically meaningful weight loss in controlled trials. Superseded by GLP-1 therapies for weight management.
Subcutaneous (research context)
Common Range
250–500 mcg/day
Timing
Morning, fasted
Frequency
Daily
Cycling
4–12 weeks
Important Note
NOT FDA-approved. Cannot be legally compounded. Efficacy not demonstrated in clinical trials.
Connect with a verified provider offering AOD 9604 therapy near you.
GLP-1 Receptor Agonist
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes and chronic weight management. It represents the leading edge of the incretin-based therapy revolution and has become one of the most widely prescribed peptide therapeutics globally. Available in both injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations.
Dual GIP/GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It represents a novel dual-incretin approach that has demonstrated superior weight loss and glycemic control compared to selective GLP-1 agonists in multiple Phase III trials.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.